Benzinga

Benzinga

Benzinga

martes, septiembre 01

Bio-Rad Laboratories Inc

BIONYSE
Trade with Public
Trade with Public
$382.67
-3.45-0.89%
Últ. Act.: Sep 1, 11:12 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Bio-Rad Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Rad Laboratories (BIO).

Price Target Range — 12 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingOutperform# Analysts4Avg. Consensus PT$334Upside to Avg. PT-12.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026RBC CapitalDan LeonardPT RaiseOutperform$370→$390
Aug 5, 2026CitigroupDaniel GrosslightPT RaiseNeutral$300→$330
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
Benzinga Newsdesk

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved